Humacyte (HUMA) Net Cash Flow (2020 - 2026)

Humacyte (HUMA) has 7 years of Net Cash Flow data on file, last reported at -$2.0 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$2.0 million, down 110.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$64.3 million (down 2338.98% YoY), and the FY2025 annual result was -$44.4 million, down 405.96% from the prior year.
• Net Cash Flow slipped to -$2.0 million in Q1 2026 per HUMA's latest filing, from $31.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $35.1 million in Q1 2024 and troughed at -$68.5 million in Q3 2025.
• A 5-year average of -$9.9 million and a median of -$17.2 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow plunged 506.64% in 2022, then jumped 273.53% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$14.0 million in 2022, then sank by 39.62% to -$19.5 million in 2023, then soared by 225.13% to $24.4 million in 2024, then gained by 27.32% to $31.1 million in 2025, then slumped by 106.31% to -$2.0 million in 2026.
• Business Quant data shows HUMA's Net Cash Flow at -$2.0 million in Q1 2026, $31.1 million in Q4 2025, and -$68.5 million in Q3 2025.